Haojie Zhu

Utilize an integrated multi-omics approach combining pharmacogenomics, proteomics, and metabonomics to identify biomarkers associated with interindividual variability in pharmacokinetics and pharmacodynamics Determine tissue-specific protein expression patterns of prodrug-activating enzymes and apply the information to prodrug design to enhance the activation and accumulation of prodrugs in target tissues Develop innovative LC-MS/MS-based technologies to address the challenges in quantifying proteins and metabolites in complex biomatrices such as blood and solid tissues

Li, J.; de Melo Jorge, D. M.; Wang, W.; Sun, S.; Frum, T.; Hang, Y.-A.; Liu, Y.; Zhou, X.; Xiao, J.; Wang, X. Spence, JR. Wobus, CE. and Zhu, H.J. Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung. Journal of Medicinal Chemistry 2024. Bhatt‐Mehta, V.; Jing, X.; Wang, X.; Zhu, H. J. Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2023.